Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational cross-sectional study to determine clinical outcomes in adults with acute migraine using at least 4 doses of ubrogepant in real-world settings

Next Previous
X
Search
Trial Profile

An observational cross-sectional study to determine clinical outcomes in adults with acute migraine using at least 4 doses of ubrogepant in real-world settings

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubrogepant (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms UNIVERSE STUDY

    • Most Recent Events

    • 26 Apr 2022 Results of a subgroup analysis assessed the real-world effectiveness of ubrogepant for the acute treatment of migraine in patients who switched to ubrogepant due to the lack of efficacy of their prior acute treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 01 Oct 2021 New trial record
    • 12 Sep 2021 Interim results (n=84) presented at The International Headache Congress - International headache Society with the European headache Federation joint congress 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top